Alpha-1 Antitrypsin Deficiency
Conditions
Brief summary
Patients with Alpha-1 Antitrypsin Deficiency (AATD) will be enrolled to receive multiple doses of ARC-AAT Injection. All subjects will require a pre-dose biopsy and a biopsy post last dose.
Detailed description
This is a multi-center, multi-dose study to evaluate the safety, tolerability and effect on intrahepatic and circulating Alpha-1 Antitrypsin (AAT) levels of ARC-AAT Injection, administered intravenously. Participants who have signed an Institutional Review Board/Ethics Committee (IRB/EC) approved informed consent form and met all of the protocol eligibility criteria will receive multiple intravenous doses (7 total doses administered every 28 days) of ARC-AAT Injection. Patients previously, currently or never receiving AAT augmentation therapy are acceptable for enrollment. All subjects will require a pre-dose biopsy and a post-dose biopsy completed after the last dose or at early termination as applicable. For each participant the duration of the study clinic visits is approximately 49 weeks, from the beginning of the Screening period to the Day 287 End-of-Study (EOS) visit. The following evaluations will be performed at regular intervals throughout the study: medical history, physical examinations, bee venom allergy blood test, vital sign measurements (blood pressure, temperature, heart rate, respiratory rate), weight, adverse events monitoring, electrocardiograms (ECGs), pregnancy tests (females), concurrent medication evaluation, pulmonary function testing, clinical laboratory tests including hematology, coagulation, chemistry, FibroTest, anti-drug antibodies, drug screens, serum AAT levels, liver biopsy, FibroScan, and urinalysis.
Interventions
RNA interference (RNAi)-based, liver-targeted therapeutic
Sponsors
Arrowhead Pharmaceuticals
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Male or non-nursing female patients 18-75 years of age, inclusive, at the time of Screening * Previous diagnosis of PiZZ genotype Alpha-1 Antitrypsin Deficiency (AATD) * Non-smoker (not a daily cigarette smoker) for at least three years with current non-smoking status confirmed by urine cotinine at screening. * Highly effective, double barrier contraception (both male and female partners) during the study and for 3 months following the last dose of ARC-AAT Injection * Suitable venous access for blood sampling
Exclusion criteria
* Known diagnosis of hepatic fibrosis from a cause other than AATD * History of poorly controlled autoimmune disease, or any history of autoimmune hepatitis * Human immunodeficiency virus (HIV) infection * Seropositive for Hepatitis B virus (HBV) or Hepatitis C virus (HCV) * Uncontrolled hypertension * History of cardiac rhythm disturbances * Symptomatic heart failure, unstable angina, myocardial infarction, severe cardiovascular disease, transient ischemic attack (TIA) or cerebrovascular accident (CVA) within 6 months prior to study entry * History of malignancy within the last 2 years except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer * History of major surgery within 1 month of Screening * Regular use of alcohol within one month prior to the Screening visit * Use of illicit drugs (such as cocaine, phencyclidine \[PCP\] and crack) within 1 year prior to Screening or positive urine drug screen at Screening * Use of an investigational agent or device within 30 days prior to dosing or current participation in an investigational study involving a therapeutic intervention * Any clinically significant history/presence of an uncontrolled systemic disease * Blood donation (≥500 mL) within 7 days prior to study treatment administration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and frequency of adverse events as a measure of safety and tolerability of multiple doses of ARC-AAT Injection | Baseline through Day 287 End-of Study Visit |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in circulating serum levels of alpha-1 antitrypsin | Baseline through Day 287 End-of Study Visit |
Countries
Canada, Ireland, Italy, Sweden
Outcome results
None listed